03 March 2015 : Clinical Research
Concurrent Chemoradiotherapy with Vinorelbine plus Split-Dose Cisplatin may be an Option in Inoperable Stage III Non-Small Cell Lung Cancer: A Single-Center ExperienceHüseyin MertsoyluABCDEFG, Fatih KöseABCDEFG, Ahmet Taner SümbülABCDEFG, Ali Murat SedefABCDEFG, Özlem DoğanABCDE, Ali Ayberk BesenABCD, Cem ParlakABCD, Alper FındıkçıoğluABC, Sadık MuallaoğluABCD, Ahmet SezerABCD, Hakan SakallıABCD, Özgür ÖzyılkanABCDEF
Med Sci Monit 2015; 21:661-666
BACKGROUND: Concurrent chemoradiotherapy is the current standard treatment for inoperable stage III non-small cell lung cancer (NSCLC). In this study we aimed to investigate the efficacy and toxicity of CCRT with split dose of cisplatin (30 mg/m2) and vinorelbine (20 mg/m2) in patients with inoperable stage III NSCLC followed in our oncology clinic.
MATERIAL AND METHODS: Medical records of 97 patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with cisplatin-vinorelbine were retrospectively analyzed. Cisplatin (30 mg/m2) and vinorelbine (20 mg/m2) were administered on days 1, 8, 22, and 29 during radiotherapy. Two cycles of consolidation chemotherapy were given. All patient data, including pathological, clinical, radiological, biochemical, and hematological data, were assessed retrospectively using our database system.
RESULTS: Our study included 97 unresectable stage III NSCLC patients who were treated with CCRT. Median age was 58 years old (range 39–75) and 87 (89.7%) of the patients were men. ECOG performance score was 0–1 in 93 patients (95.9%). Squamous histology, the most common histology, was diagnosed in 46 patients (47.4%). Median follow-up time was 23.8 months. Median progression-free survival (PFS) and median overall survival time (OS) were 10.3 months and 17.8 months, respectively. Objective response rate and clinical benefit rate were 75.3% and 83.5%, respectively. Distant and local relapse rate were 57.1% and 42.9%, respectively. Hematological and non-hematological grade 3–4 toxicities were seen in 13 (13.4%) and 16 (16.5%) patients, respectively. Six (6.1%) patients died due to toxicity.
CONCLUSIONS: The results of this study suggest that split-dose cisplatin may offer fewer grade III–IV toxicities without sacrificing efficacy and could be an option in patients with inoperable stage III NSCLC during CCRT. Similar to past studies, despite high response rate during CCRT, distant relapse is the major parameter that influences patient survival in long-term in NSCLC.
Keywords: Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Carcinoma, Non-Small-Cell Lung - therapy, Chemoradiotherapy - adverse effects, Cisplatin - therapeutic use, Consolidation Chemotherapy, Disease-Free Survival, Dose-Response Relationship, Drug, Kaplan-Meier Estimate, Lung Neoplasms - therapy, Neoplasm Staging, Vinblastine - therapeutic use
01 May 2022 : EditorialEditorial: Cardiovascular Complications at One Year After SARS-CoV-2 Infection are Independent of Underlying Cardiovascular Risk Factors or Severity of COVID-19
Med Sci Monit 2022; 28:e937048
16 May 2022 : Clinical ResearchImportance of Influenza Anti-Hemagglutinin Antibodies During the SARS-CoV-2 Pandemic in the 2019/2020 Epide...
Med Sci Monit In Press; DOI: 10.12659/MSM.936495
04 May 2022 : Clinical ResearchEffects of Wearing Face Masks on Exercise Capacity and Ventilatory Anaerobic Threshold in Healthy Subjects ...
Med Sci Monit In Press; DOI: 10.12659/MSM.936069
22 April 2022 : Clinical ResearchFactors Associated with Falls During Hospitalization for Coronavirus Disease 2019 (COVID-19)
Med Sci Monit In Press; DOI: 10.12659/MSM.936547
18 May 2022 : Clinical ResearchPhysical and Psychosocial Concept Domains Related to Health-Related Quality of Life (HRQL) in 50 Girls and ...
Med Sci Monit In Press; DOI: 10.12659/MSM.936801
18 May 2022 : Clinical ResearchAssociation Between Variants of the Mannose-Binding Lectin 2 Gene and Susceptibility to Sepsis in the Haina...
Med Sci Monit In Press; DOI: 10.12659/MSM.936134
17 May 2022 : Clinical ResearchClinical Application of C-TIRADS Category and Contrast-Enhanced Ultrasound in Differential Diagnosis of Sol...
Med Sci Monit In Press; DOI: 10.12659/MSM.936368
Most Viewed Current Articles
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292
01 Nov 2020 : Review articleLong-Term Respiratory and Neurological Sequelae of COVID-19
Med Sci Monit 2020; 26:e928996